Semprus BioSciences to develop anti-biofilm endotracheal tube to reduce VAP infections with aid from US Army's ATRC fund.
M2 EQUITYBITES-November 9, 2012-Semprus BioSciences to develop anti-biofilm endotracheal tube to reduce VAP infections with aid from US Army's ATRC fund(C)2012 M2 COMMUNICATIONS http://www.m2.com
Medical device company Teleflex Incorporated (NYSE:TFX) reported on Thursday the receipt of the initial phase of a USD2.3m research grant from the US Army's Telemedicine and Advanced Technology Research Centre (TATRC) in Fort Detrick, MD.
This grant has been awarded to the company's wholly owned subsidiary, Semprus BioSciences, which plans to use the fund to support the research and development of a surface-modified endotracheal tube that combines the Semprus Sustain Technology with the delivery of antimicrobials.
The research will reportedly be conducted at Semprus' facilities in Cambridge, MA, in conjunction with the US Army Institute for Surgical Research (USAISR) at Fort Sam Houston in San Antonio, TX.
When patients requiring respiratory support are ventilated in intensive care units( ICU) for extended periods of time, bacterial adherence to the endotracheal tube is considered the first step in developing a lung infection, or ventilator-associated pneumonia (VAP), said the company.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Publication:||M2 EquityBites (EQB)|
|Date:||Nov 9, 2012|
|Previous Article:||Piedmont RIA invests in Syntellia.|
|Next Article:||Balchem Corporation elects Richard A. Bendure as COO.|